COVID-19 vaccination for hematopoietic stem cell transplant patients

The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular,...

Results of phase III DEVENT trial show improved survival outcomes with ruxolitinib in U.S. participants

Ruxolitinib is a JAK1/2 inhibitor currently approved for the treatment of myelofibrosis,...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

What needs to be considered in patients with MPN with COVID-19?

During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We...

Which factors may impact transplantation outcomes in patients with MF?

During the 2021 ASCO Annual Meeting, the MPN Hub spoke with Jan Philipp Bewersdorf, Yale School of Medicine, New Haven, US. We...

Gene expression signature as a risk stratification tool for patients with myelofibrosis

Myelofibrosis (MF) is a complex hematologic disorder that develops due to certain mutations in hematopoietic...

What is the impact of pre-treatment ruxolitinib on patients with MF receiving allo-HSCT? An EBMT CMWP study

Most patients (89%) diagnosed with myelofibrosis (MF) present with splenomegaly, and new or...

Editorial Theme | The management of relapsed/refractory myelofibrosis: Part 4 – investigational combination approaches

The unmet clinical need in treating patients with relapsed or refractory...

FDA biologics license application of ropeginterferon alfa-2b resubmitted for the treatment of PV

Polycythemia vera (PV) is a subtype of myeloproliferative neoplasms, characterized by excessive red...

5-year results from the PROUD-PV and CONTINUATION-PV studies

Ropeginterferon alfa-2b is a novel pegylated recombinant interferon, approved in the EU as monotherapy for the treatment of adults with...

ASH 2020: Highlights for polycythemia vera

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital,...

Interferon therapy in the management of myeloproliferative neoplasms

Treatment with interferon (IFN) therapy is considered successful for patients with myeloproliferative neoplasms (MPN), such as...